Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

MM01-21

A Phase II Study of Daily Thalidomide, Oral Cytoxan and Prednisone for Relapsed or Refractory Multiple Myeloma

Abstracts/Posters/Presentations:

  • Rafat Abonour, Kristen Ganjoo, Christopher Fausel, Constantin Yiannoutsos, Beth E. Juliar, Lisa Wood, Gina Smith, Paul Walker, Larry Cripe. A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma, A Hoosier Oncology Group Trial: MM01-21. Accepted as a poster presentation for ASH Annual Meeting December 6-9, 2003, San Diego, CA.
  • Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: MM01-21. Accepted as a poster presentation for the ASCO Annual Meeting, May 13 – 17, 2005, Orlando, FL

Manuscripts/Articles:

  • Attaya Suvannasankha, Christopher Fausel, Beth E. Juliar, Constantin T. Yiannoutsos, William B. Fisher, Rafat H. Ansari, Lisa L. Wood, Gina G. Smith, Larry D. Cripe, Rafat Abonour. Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: MM01-21. The Oncologist, Vol. 12, No. 1, 99-106, January 2007